Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Organogenesis Holdings Q3 2026 Results: Net Loss of $29.6M

Organogenesis Holdings Inc. reported a significant decline in net product revenue to $45.5 million for the quarter ended September 30, 2026, compared to $150.5 million in the prior year. The company experienced a net loss of $29.6 million for the quarter and $179.1 million for the nine-month period, driven by lower sales and a $30.1 million income tax expense related to the valuation of deferred tax assets.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue45.5150.9
Profit before tax-29.621.2
Net income-29.621.6
EPS (diluted, $ a share)$-0.25$0.11

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-69.9%
Operating margin-64.9%
Source

10-Q filed with the SEC, NASDAQ: ORGO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Organogenesis Holdings Inc.: key numbers

Share price
$0.8031Close, Nov 16
Market cap
$104M
Shares outstanding
129.8MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Organogenesis Holdings Inc.

All →
4:15 PM ET 8-K
Financial Results

Organogenesis Holdings Financial Results

Organogenesis Holdings Inc. reported third quarter 2026 financial results, showing a significant 70% year-over-year revenue decline to $45.5 million. The company posted a net loss of $29.6 million as it navigates what management described as a 'market reset' in the advanced wound care sector. Despite the year-over-year drop, management noted sequential revenue growth and broad-based market share gains across its portfolio.

Term
3 months

“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust. Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”

Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.